News
MyChesCo on MSN1d
Expanded Recommendation for GSK’s AREXVY Vaccine Targets Adults at Higher Risk for Severe RSVThe Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...
Investor's Business Daily on MSN2d
Stocks Generating Improved Relative Strength: GSK ADRRating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
Goldman Sachs says the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices published its final agenda ...
GSK plc (LSE/NYSE: GSK) has today released global survey data showing that over half (52%) of people aged 50-60 feel younger ...
In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon.
UK pharm major GSK (LSE: GSK) has breached the ABPI Code of Practice for the Industry and brought discredit upon, and ...
A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...
GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...
CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...
Abu Dhabi, brings together key partners including PureHealth’s Rafed, AD Ports Group’s Khalifa Economic Zones Abu Dhabi (KEZAD), Abu ...
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback